Advanced search
Publication Cover
Future Oncology Volume 5, 2009 - Issue 9
Submit an article Journal homepage
428
Views
0
CrossRef citations to date
0
Altmetric
Review

Molecular and Cellular Biology of Rhabdomyosarcoma

Carla De Giovannia Department of Experimental Pathology, Cancer Research Section, University of Bologna, Bologna, ItalyView further author information
,
Lorena Landuzzib Laboratory of Experimental Oncology, Rizzoli Orthopaedic Institute, Bologna, ItalyView further author information
,
Giordano Nicolettib Laboratory of Experimental Oncology, Rizzoli Orthopaedic Institute, Bologna, ItalyView further author information
,
Pier-Luigi Lollinic Department of Hematology and Oncological Sciences ‘L. e A. Seragnoli‘, Viale Filopanti 22, Bologna40126, Italy. [email protected]Correspondence[email protected]
View further author information
&
Patrizia Nannia Department of Experimental Pathology, Cancer Research Section, University of Bologna, Bologna, ItalyView further author information
Pages 1449-1475 | Published online: 10 Nov 2009

Bibliography

  • Weiss SW , GoldblumJR: Rhabdomyosarcoma. In: Enzinger and Weiss’s Soft Tissue Tumors. MO, USA, 785–835 (2001).
  • Parham DM , EllisonDA: Rhabdomyosarcomas in adults and children: an update.Arch. Pathol. Lab. Med.130(10), 1454–1465 (2006).
  • Paulino AC , OkcuMF: Rhabdomyosarcoma.Curr. Probl. Cancer32(1), 7–34 (2008).
  • Ognjanovic S , LinaberyAM, CharbonneauB, RossJA: Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005.Cancer115(18), 4218–4226 (2009).
  • Tsokos M , WebberBL, ParhamDMet al.: Rhabdomyosarcoma. A new classification scheme related to prognosis.Arch. Pathol. Lab. Med.116(8), 847–855 (1992).
  • Parham DM , ShapiroDN, DowningJR, WebberBL, DouglassEC: Solid alveolar rhabdomyosarcomas with the t(2;13). Report of two cases with diagnostic implications.Am. J. Surg. Pathol.18(5), 474–478 (1994).
  • Newton WA Jr , GehanEA, WebberBLet al.: Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification – an intergroup rhabdomyosarcoma study.Cancer76(6), 1073–1085 (1995).
  • Charytonowicz E , Cordon-CardoC, MatushanskyI, ZimanM: Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?Cancer Lett.279(2), 126–136 (2009).
  • Davicioni E , AndersonMJ, FinckensteinFGet al.: Molecular classification of rhabdomyosarcoma – genotypic and phenotypic determinants of diagnosis: a report from the Children’s Oncology Group.Am. J. Pathol.174(2), 550–564 (2009).
  • Meza JL , AndersonJ, PappoAS, MeyerWH: Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group.J. Clin. Oncol.24(24), 3844–3851 (2006).
  • Oberlin O , ReyA, LydenEet al.: Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.J. Clin. Oncol.26(14), 2384–2389 (2008).
  • Merlino G , HelmanLJ: Rhabdomyosarcoma – working out the pathways.Oncogene18(38), 5340–5348 (1999).
  • Buckingham M , BajardL, ChangTet al.: The formation of skeletal muscle: from somite to limb.J. Anat.202(1), 59–68 (2003).
  • Berkes CA , TapscottSJ: MyoD and the transcriptional control of myogenesis.Semin. Cell Dev. Biol.16(4–5), 585–595 (2005).
  • Buckingham M , MontarrasD: Skeletal muscle stem cells.Curr. Opin. Genet. Dev.18(4), 330–336 (2008).
  • Morotti RA , NicolKK, ParhamDMet al.: An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children’s Oncology Group experience.Am. J. Surg. Pathol.30(8), 962–968 (2006).
  • Heerema-McKenney A , WijnaendtsLC, PulliamJFet al.: Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.Am. J. Surg. Pathol.32(10), 1513–1522 (2008).
  • Sultan I , QaddoumiI, YaserS, Rodriguez-GalindoC, FerrariA: Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.J. Clin. Oncol.27(20), 3391–3397 (2009).
  • Sorensen PH , LynchJC, QualmanSJet al.: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group.J. Clin. Oncol.20(11), 2672–2679 (2002).
  • Breneman JC , LydenE, PappoASet al.: Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – a report from the Intergroup Rhabdomyosarcoma Study IV.J. Clin. Oncol.21(1), 78–84 (2003).
  • Mercado GE , BarrFG: Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances.Curr. Mol. Med.7(1), 47–61 (2007).
  • Slater O , ShipleyJ: Clinical relevance of molecular genetics to paediatric sarcomas.J. Clin. Pathol.60(11), 1187–1194 (2007).
  • Davis RJ , BennicelliJL, MacinaRA, NycumLM, BiegelJA, BarrFG: Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma.Hum. Mol. Genet.4(12), 2355–2362 (1995).
  • Barr FG , QualmanSJ, MacrisMHet al.: Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.Cancer Res.62(16), 4704–4710 (2002).
  • Wachtel M , DettlingM, KoscielniakEet al.: Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.Cancer Res.64(16), 5539–5545 (2004).
  • Hosoi H , KakazuN, KonishiEet al.: A novel PAX3 rearrangement in embryonal rhabdomyosarcoma.Cancer Genet. Cytogenet.189(2), 98–104 (2009).
  • Meloni-Ehrig A , SmithB, ZgodaJet al.: Translocation (2;8)(q35;q13): a recurrent abnormality in congenital embryonal rhabdomyosarcoma.Cancer Genet. Cytogenet.191(1), 43–45 (2009).
  • Helman LJ , MeltzerP: Mechanisms of sarcoma development.Nat. Rev. Cancer3(9), 685–694 (2003).
  • Scrable H , CaveneeW, GhavimiF, LovellM, MorganK, SapienzaC: A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting.Proc. Natl Acad. Sci. USA86(19), 7480–7484 (1989).
  • Besnard-Guerin C , NewshamI, WinqvistR, CaveneeWK: A common region of loss of heterozygosity in Wilms’ tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5.Hum. Genet.97(2), 163–170 (1996).
  • Visser M , SijmonsC, BrasJet al.: Allelotype of pediatric rhabdomyosarcoma.Oncogene15(11), 1309–1314 (1997).
  • Smith AC , ChoufaniS, FerreiraJC, WeksbergR: Growth regulation, imprinted genes, and chromosome 11p15.5.Pediatr. Res.61(5 Pt 2), 43R–47R (2007).
  • Cavenee WK , HansenMF, ScrableHJ, JamesCD: Loss of genetic information in cancer.Ciba Found. Symp.142, 79–88 (1989).
  • Pedone PV , TiraboscoR, CavazzanaAOet al.: Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors.Hum. Mol. Genet.3(7), 1117–1121 (1994).
  • Zhan S , ShapiroDN, HelmanLJ: Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma.J. Clin. Invest.94(1), 445–448 (1994).
  • Casola S , PedonePV, CavazzanaAOet al.: Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma.Oncogene14(12), 1503–1510 (1997).
  • Anderson J , GordonA, McManusA, ShipleyJ, Pritchard-JonesK: Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma.Neoplasia1(4), 340–348 (1999).
  • Bridge JA , LiuJ, WeiboltVet al.: Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study.Genes Chromosomes Cancer27(4), 337–344 (2000).
  • Khan J , SimonR, BittnerMet al.: Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.Cancer Res.58(22), 5009–5013 (1998).
  • Khan J , WeiJS, RingnerMet al.: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks.Nat. Med.7(6), 673–679 (2001).
  • Henderson SR , GuilianoD, PresneauNet al.: A molecular map of mesenchymal tumors.Genome Biol.6(9), R76 (2005).
  • Schaaf GJ , RuijterJM, van RuissenFet al.: Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries.FASEB J.19(3), 404–406 (2005).
  • De Pittà C , TombolanL, AlbieroGet al.: Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors.Int. J. Cancer118(11), 2772–2781 (2006).
  • Missiaglia E , SelfeJ, HamdiMet al.: Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.Genes Chromosomes Cancer48(6), 455–467 (2009).
  • Davicioni E , FinckensteinFG, ShahbazianV: Identification of a PAX–FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.Cancer Res.66(14), 6936–6946 (2006).
  • Laè M , AhnEH, MercadoGEet al.: Global gene expression profiling of PAX–FKHR fusion-positive alveolar and PAX–FKHR fusion-negative embryonal rhabdomyosarcomas.J. Pathol.212(2), 143–151 (2007).
  • Romualdi C , De PittaC, TombolanLet al.: Defining the gene expression signature of rhabdomyosarcoma by meta-analysis.BMC Genomics7, 287 (2006).
  • Baer C , NeesM, BreitSet al.: Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing’s sarcoma.Int. J. Cancer110(5), 687–694 (2004).
  • Roberts I , WienbergJ, NachevaE, GraceC, GriffinD, ColemanN: Novel method for the production of multiple colour chromosome paints for use in karyotyping by fluorescence in situ hybridisation.Genes Chromosomes Cancer25(3), 241–250 (1999).
  • Martinez-Ramirez A , Rodriguez-PeralesS, MelendezBet al.: Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques.Cancer Genet. Cytogenet.141(2), 138–142 (2003).
  • Barr FG , NautaLE, DavisRJ, SchaferBW, NycumLM, BiegelJA: In vivo amplification of the PAX3–FKHR and PAX7–FKHR fusion genes in alveolar rhabdomyosarcoma.Hum. Mol. Genet.5(1), 15–21 (1996).
  • Davis RJ , BarrFG: Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.Proc. Natl Acad. Sci. USA94(15), 8047–8051 (1997).
  • Fitzgerald JC , ScherrAM, BarrFG: Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma.Cancer Genet. Cytogenet.117(1), 37–40 (2000).
  • Bennicelli JL , EdwardsRH, BarrFG: Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.Proc. Natl Acad. Sci. USA93(11), 5455–5459 (1996).
  • Scheidler S , FredericksWJ, RauscherFJIII, BarrFG, VogtPK: The hybrid PAX3–FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.Proc. Natl Acad. Sci. USA93(18), 9805–9809 (1996).
  • Khan J , BittnerML, SaalLHet al.: cDNA microarrays detect activation of a myogenic transcription program by the PAX3–FKHR fusion oncogene.Proc. Natl Acad. Sci. USA96(23), 13264–13269 (1999).
  • Lam PY , SublettJE, HollenbachAD, RousselMF: The oncogenic potential of the Pax3–FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.Mol. Cell. Biol.19(1), 594–601 (1999).
  • Zhang L , WangC: PAX3–FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression.J. Biol. Chem.278(1), 27–36 (2003).
  • Taulli R , ScuoppoC, BersaniFet al.: Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.Cancer Res.66(9), 4742–4749 (2006).
  • Scuoppo C , RiessI, Schmitt-NeyMet al.: The oncogenic transcription factor PAX3–FKHR can convert fibroblasts into contractile myotubes.Exp. Cell Res.313(11), 2308–2317 (2007).
  • Linardic CM , DownieDL, QualmanS, BentleyRC, CounterCM: Genetic modeling of human rhabdomyosarcoma.Cancer Res.65(11), 4490–4495 (2005).
  • Naini S , EtheridgeKT, AdamSJet al.: Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.Cancer Res.68(23), 9583–9588 (2008).
  • Ren YX , FinckensteinFG, AbduevaDAet al.: Mouse mesenchymal stem cells expressing PAX–FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations.Cancer Res.68(16), 6587–6597 (2008).
  • Bernasconi M , RemppisA, FredericksWJ, RauscherFJIII, SchaferBW: Induction of apoptosis in rhabdomyosarcoma cells through downregulation of PAX proteins.Proc. Natl Acad. Sci. USA93(23), 13164–13169 (1996).
  • Fredericks WJ , AyyanathanK, HerlynM, FriedmanJR, RauscherFJ3rd: An engineered PAX3–KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3–FKHR oncogene.Mol. Cell. Biol.20(14), 5019–5031 (2000).
  • Ebauer M , WachtelM, NiggliFK, SchaferBW: Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR.Oncogene26(51), 7267–7281 (2007).
  • Kikuchi K , TsuchiyaK, OtabeOet al.: Effects of PAX3–FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.Biochem. Biophys. Res. Commun.365(3), 568–574 (2008).
  • Linardic CM : PAX3–FOXO1 fusion gene in rhabdomyosarcoma.Cancer Lett.270(1), 10–18 (2008).
  • Begum S , EmamiN, CheungA, WilkinsO, DerS, HamelPA: Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR.Oncogene24(11), 1860–1872 (2005).
  • Epstein JA , SongB, LakkisM, WangC: Tumor-specific PAX3–FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor a receptor.Mol. Cell. Biol.18(7), 4118–4130 (1998).
  • Mercado GE , XiaSJ, ZhangCet al.: Identification of PAX3–FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.Genes Chromosomes Cancer47(6), 510–520 (2008).
  • Robson EJ , HeSJ, EcclesMR: A PANorama of PAX genes in cancer and development.Nat. Rev. Cancer6(1), 52–62 (2006).
  • Margue CM , BernasconiM, BarrFG, SchaferBW: Transcriptional modulation of the anti-apoptotic protein BCL-xL by the paired box transcription factors PAX3 and PAX3/FKHR.Oncogene19(25), 2921–2929 (2000).
  • Li HG , WangQ, LiHMet al.: PAX3 and PAX3–FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN.Cancer Lett.253(2), 215–223 (2007).
  • Anastasi S , GiordanoS, SthandierOet al.: A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation.J. Cell Biol.137(5), 1057–1068 (1997).
  • Roeb W , BoyerA, CaveneeWK, ArdenKC: PAX3–FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.Proc. Natl Acad. Sci. USA104(46), 18085–18090 (2007).
  • Barber TD , BarberMC, TomescuO, BarrFG, RubenS, FriedmanTB: Identification of target genes regulated by PAX3 and PAX3–FKHR in embryogenesis and alveolar rhabdomyosarcoma.Genomics79(3), 278–284 (2002).
  • Gee MF , TsuchidaR, Eichler-JonssonC, DasB, BaruchelS, MalkinD: Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.Oncogene24(54), 8025–8037 (2005).
  • Onisto M , SlongoML, GregnaninL, GastaldiT, CarliM, RosolenA: Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.Int. J. Oncol.27(3), 791–798 (2005).
  • Nabarro S , HimoudiN, PapanastasiouAet al.: Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3–FKHR fusion oncoprotein.J. Exp. Med.202(10), 1399–1410 (2005).
  • Tomescu O , XiaSJ, StrezleckiDet al.: Inducible short-term and stable long-term cell culture systems reveal that the PAX3–FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression.Lab. Invest.84(8), 1060–1070 (2004).
  • Chen Y , TakitaJ, MizuguchiMet al.: Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression.Genes Chromosomes Cancer46(4), 348–358 (2007).
  • El-Badry OM , MinnitiC, KohnEC, HoughtonPJ, DaughadayWH, HelmanLJ: Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.Cell Growth Differ.1(7), 325–331 (1990).
  • Makawita S , HoM, DurbinAD, ThornerPS, MalkinD, SomersGR: Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF2 expression is associated with translocation-negative tumors.Pediatr. Dev. Pathol.12(2), 127–135 (2009).
  • Steigen SE , SchaefferDF, WestRB, NielsenTO: Expression of insulin-like growth factor 2 in mesenchymal neoplasms.Mod. Pathol.22(7), 914–921 (2009).
  • Rikhof B , de JongS, SuurmeijerAJ, MeijerC, van der GraafWT: The insulin-like growth factor system and sarcomas.J. Pathol.217(4), 469–482 (2009).
  • Baserga R , PeruzziF, ReissK: The IGF-1 receptor in cancer biology.Int. J. Cancer107(6), 873–877 (2003).
  • Pollak M : Insulin and insulin-like growth factor signalling in neoplasia.Nat. Rev. Cancer8(12), 915–928 (2008).
  • Kim SY , ToretskyJA, ScherD, HelmanLJ: The role of IGF-1R in pediatric malignancies.Oncologist14(1), 83–91 (2009).
  • Baserga R : Customizing the targeting of IGF-1 receptor.Future Oncol.5(1), 43–50 (2009).
  • Blandford MC , BarrFG, LynchJC, RandallRL, QualmanSJ, KellerC: Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children’s Oncology Group.Pediatr. Blood Cancer46(3), 329–338 (2006).
  • Ayalon D , GlaserT, WernerH: Transcriptional regulation of IGF-I receptor gene expression by the PAX3–FKHR oncoprotein.Growth Horm. IGF Res.11(5), 289–297 (2001).
  • Xiong L , KouF, YangY, WuJ: A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop.J. Cell Biol.178(6), 995–1007 (2007).
  • Scotlandi K , PicciP: Targeting insulin-like growth factor 1 receptor in sarcomas.Curr. Opin. Oncol.20(4), 419–427 (2008).
  • Shapiro DN , JonesBG, ShapiroLH, DiasP, HoughtonPJ: Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma.J. Clin. Invest.94(3), 1235–1242 (1994).
  • Kalebic T , TsokosM, HelmanLJ: In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and downregulates p34cdc2.Cancer Res.54(21), 5531–5534 (1994).
  • Cao L , YuY, DarkoIet al.: Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.Cancer Res.68(19), 8039–8048 (2008).
  • Cen L , HsiehFC, LinHJ, ChenCS, QualmanSJ, LinJ: PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.Br. J. Cancer97(6), 785–791 (2007).
  • Petricoin EF 3rd , EspinaV, AraujoRPet al.: Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.Cancer Res.67(7), 3431–3440 (2007).
  • Cai X , CullenBR: The imprinted H19 noncoding RNA is a primary microRNA precursor.RNA13(3), 313–316 (2007).
  • Cam H , GriesmannH, BeitzingerMet al.: p53 family members in myogenic differentiation and rhabdomyosarcoma development.Cancer Cell10(4), 281–293 (2006).
  • Keleti J , QuezadoMM, AbazaMM, RaffeldM, TsokosM: The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.Am. J. Pathol.149(1), 143–151 (1996).
  • Taylor AC , ShuL, DanksMKet al.: P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.Med. Pediatr. Oncol.35(2), 96–103 (2000).
  • Xia SJ , PresseyJG, BarrFG: Molecular pathogenesis of rhabdomyosarcoma.Cancer Biol. Ther.1(2), 97–104 (2002).
  • Takahashi Y , OdaY, KawaguchiKet al.: Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.Mod. Pathol.17(6), 660–669 (2004).
  • Ragazzini P , GamberiG, PazzagliaLet al.: Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma.Histol. Histopathol.19(2), 401–411 (2004).
  • Iolascon A , FaienzaMF, CoppolaBet al.: Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma.Genes Chromosomes Cancer15(4), 217–222 (1996).
  • Lang GA , IwakumaT, SuhYAet al.: Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome.Cell119(6), 861–872 (2004).
  • Olive KP , TuvesonDA, RuheZCet al.: Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome.Cell119(6), 847–860 (2004).
  • Kohashi K , OdaY, YamamotoHet al.: Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.J. Cancer Res. Clin. Oncol.134(10), 1097–1103 (2008).
  • Kleinerman RA , TuckerMA, AbramsonDH, SeddonJM, TaroneRE, FraumeniJFJr: Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.J. Natl Cancer Inst.99(1), 24–31 (2007).
  • Marees T , MollAC, ImhofSM, de BoerMR, RingensPJ, van LeeuwenFE: Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.J. Natl Cancer Inst.100(24), 1771–1779 (2008).
  • Anderson J , GordonA, Pritchard-JonesK, ShipleyJ: Genes, chromosomes, and rhabdomyosarcoma.Genes Chromosomes Cancer26(4), 275–285 (1999).
  • Bridge JA , LiuJ, QualmanSJet al.: Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes.Genes Chromosomes Cancer33(3), 310–321 (2002).
  • Williamson D , SelfeJ, GordonTet al.: Role for amplification and expression of glypican-5 in rhabdomyosarcoma.Cancer Res.67(1), 57–65 (2007).
  • Barr FG , DuanF, SmithLMet al.: Genomic and clinical analyses of 2p24 and 12q13–q14 amplification in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group.Genes Chromosomes Cancer48(8), 661–672 (2009).
  • Toffolatti L , FrascellaE, NinfoVet al.: MYCN expression in human rhabdomyosarcoma cell lines and tumour samples.J. Pathol.196(4), 450–458 (2002).
  • Williamson D , LuYJ, GordonTet al.: Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype.J. Clin. Oncol.23(4), 880–888 (2005).
  • Chen Y , TakitaJ, HiwatariMet al.: Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.Genes Chromosomes Cancer45(6), 583–591 (2006).
  • Langenau DM , KeefeMD, StorerNYet al.: Effects of RAS on the genesis of embryonal rhabdomyosarcoma.Genes Dev.21(11), 1382–1395 (2007).
  • Kratz CP , SteinemannD, NiemeyerCMet al.: Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome.Hum. Mol. Genet.16(4), 374–379 (2007).
  • Astolfi A , NanniP, LanduzziLet al.: An anti-apoptotic role for NGF receptors in human rhabdomyosarcoma.Eur. J. Cancer37(13), 1719–1725 (2001).
  • Croci S , LanduzziL, AstolfiAet al.: Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells.Cancer Res.64(5), 1730–1736 (2004).
  • Goldstein M , MellerI, Orr-UrtregerA: FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5´ CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes.Genes Chromosomes Cancer46(11), 1028–1038 (2007).
  • Kurmasheva RT , HarwoodFC, HoughtonPJ: Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors.Mol. Cancer Ther.6(5), 1620–1628 (2007).
  • Ricci C , LanduzziL, RossiIet al.: Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells.Int. J. Cancer87(1), 29–36 (2000).
  • Ganti R , SkapekSX, ZhangJet al.: Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma.Mod. Pathol.19(9), 1213–1220 (2006).
  • Wachtel M , RungeT, LeuschnerIet al.: Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry.J. Clin. Oncol.24(5), 816–822 (2006).
  • De Giovanni C , LanduzziL, FrabettiFet al.: Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells.Cancer Res.56(17), 3898–3901 (1996).
  • Ricci C , PolitoL, NanniPet al.: HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells.J. Immunother.25(4), 314–323 (2002).
  • Armistead PM , SalganickJ, RohJSet al.: Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients.Cancer110(10), 2293–2303 (2007).
  • Ferracini R , OliveroM, Di RenzoMFet al.: Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas.Oncogene12(8), 1697–1705 (1996).
  • Rees H , WilliamsonD, PapanastasiouAet al.: The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas.Growth Factors24(3), 197–208 (2006).
  • Sharp R , RecioJA, JhappanCet al.: Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.Nat. Med.8(11), 1276–1280 (2002).
  • Taniguchi E , NishijoK, McCleishATet al.: PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma.Oncogene27(51), 6550–6560 (2008).
  • Nanni P , NicolettiG, PalladiniAet al.: Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4.Mol. Cancer Ther.8(4), 754–761 (2009).
  • Ohali A , AvigadS, NaumovI, GoshenY, AshS, YanivI: Different telomere maintenance mechanisms in alveolar and embryonal rhabdomyosarcoma.Genes Chromosomes Cancer47(11), 965–970 (2008).
  • Caldas H , HollowayMP, HallBM, QualmanSJ, AlturaRA: Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo.J. Med. Genet.43(2), 119–128 (2006).
  • Bryson-Richardson RJ , CurriePD: The genetics of vertebrate myogenesis.Nat. Rev. Genet.9(8), 632–646 (2008).
  • Gayraud-Morel B , ChretienF, TajbakhshS: Skeletal muscle as a paradigm for regenerative biology and medicine.Regen. Med.4(2), 293–319 (2009).
  • Messina G , CossuG: The origin of embryonic and fetal myoblasts: a role of Pax3 and Pax7.Genes Dev.23(8), 902–905 (2009).
  • Bois PR , GrosveldGC: FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts.EMBO J.22(5), 1147–1157 (2003).
  • Wu AL , KimJH, ZhangC, UntermanTG, ChenJ: Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components.Endocrinology149(3), 1407–1414 (2008).
  • van Rooij E , LiuN, OlsonEN: MicroRNAs flex their muscles.Trends Genet.24(4), 159–166 (2008).
  • Williams AH , LiuN, van RooijE, OlsonEN: MicroRNA control of muscle development and disease.Curr. Opin. Cell Biol.21(3), 461–469 (2009).
  • Wang H , GarzonR, SunHet al.: NF-kB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma.Cancer Cell14(5), 369–381 (2008).
  • Ren H , YinP, DuanC: IGFBP-5 regulates muscle cell differentiation by binding to IGF-II and switching on the IGF-II auto-regulation loop.J. Cell Biol.182(5), 979–991 (2008).
  • Graf Finckenstein F , ShahbazianV, DavicioniE, RenYX, AndersonMJ: PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis.Oncogene27(14), 2004–2014 (2008).
  • Lang D , LuMM, HuangLet al.: Pax3 functions at a nodal point in melanocyte stem cell differentiation.Nature433(7028), 884–887 (2005).
  • Olguin HC , YangZ, TapscottSJ, OlwinBB: Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination.J. Cell Biol.177(5), 769–779 (2007).
  • Subramanian S , LuiWO, LeeCHet al.: MicroRNA expression signature of human sarcomas.Oncogene27(14), 2015–2026 (2008).
  • Ciarapica R , RussoG, VerginelliFet al.: Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma.Cell Cycle8(1), 172–175 (2009).
  • Taulli R , BersaniF, FoglizzoVet al.: The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.J. Clin. Invest.119(8), 2366–2378 (2009).
  • Hahn H , WojnowskiL, SpechtKet al.: Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma.J. Biol. Chem.275(37), 28341–28344 (2000).
  • Perk K , ShachatDA, MoloneyJB: Pathogenesis of a rhabdomyosarcoma (undifferentiated type) in rats induced by a murine sarcoma virus (Moloney).Cancer Res.28(6), 1197–1206 (1968).
  • Nanni P , AzzarelloG, TessarolloLet al.: In vitro differentiation of rhabdomyosarcomas induced by nickel or by Moloney murine sarcoma virus.Br. J. Cancer63(5), 736–742 (1991).
  • Gilman JP : Metal carcinogenesis. II. A study on the carcinogenic activity of cobalt, copper, iron, and nickel compounds.Cancer Res.22, 158–162 (1962).
  • Kirkpatrick CJ , AlvesA, KohlerHet al.: Biomaterial-induced sarcoma: A novel model to study preneoplastic change.Am. J. Pathol.156(4), 1455–1467 (2000).
  • Hansen T , ClermontG, AlvesAet al.: Biological tolerance of different materials in bulk and nanoparticulate form in a rat model: sarcoma development by nanoparticles.J. R. Soc. Interface3(11), 767–775 (2006).
  • Lindor NM , McMasterML, LindorCJ, GreeneMH: Concise handbook of familial cancer susceptibility syndromes – second edition.J. Natl Cancer Inst. Monogr. (38), 1–93 (2008).
  • Ferrari A , BisognoG, MacalusoAet al.: Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1.Cancer109(7), 1406–1412 (2007).
  • Gorlin RJ : Nevoid basal cell carcinoma (Gorlin) syndrome.Genet. Med.6(6), 530–539 (2004).
  • Hanks S , ColemanK, SummersgillBet al.: Comparative genomic hybridization and BUB1B mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome.Cancer Lett.239(2), 234–238 (2006).
  • Kratz CP , HolterS, EtzlerJet al.: Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome.J. Med. Genet.46(6), 418–420 (2009).
  • Grufferman S , RuymannF, OgnjanovicS, ErhardtEB, MaurerHM: Prenatal X-ray exposure and rhabdomyosarcoma in children: a report from the children’s oncology group.Cancer Epidemiol. Biomarkers Prev.18(4), 1271–1276 (2009).
  • Harvey M , McArthurMJ, MontgomeryCAJr, ButelJS, BradleyA, DonehowerLA: Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.Nat. Genet.5(3), 225–229 (1993).
  • Jacks T , RemingtonL, WilliamsBOet al.: Tumor spectrum analysis in p53-mutant mice.Curr. Biol.4(1), 1–7 (1994).
  • Hahn H , WojnowskiL, ZimmerAM, HallJ, MillerG, ZimmerA: Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome.Nat. Med.4(5), 619–622 (1998).
  • Takayama H , LaRochelleWJ, SharpRet al.: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor.Proc. Natl Acad. Sci. USA94(2), 701–706 (1997).
  • Teitz T , ChangJC, KitamuraM, YenTS, KanYW: Rhabdomyosarcoma arising in transgenic mice harboring the β-globin locus control region fused with simian virus 40 large T antigen gene.Proc. Natl Acad. Sci. USA90(7), 2910–2914 (1993).
  • Galindo RL , AllportJA, OlsonEN: A Drosophila model of the rhabdomyosarcoma initiator PAX7–FKHR.Proc. Natl Acad. Sci. USA103(36), 13439–13444 (2006).
  • Nanni P , NicolettiG, De GiovanniCet al.: Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.Cancer Res.63(11), 2728–2732 (2003).
  • Fleischmann A , JochumW, EferlR, WitowskyJ, WagnerEF: Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene.Cancer Cell4(6), 477–482 (2003).
  • Keller C , ArenkielBR, CoffinCM, El-BardeesyN, DePinhoRA, CapecchiMR: Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.Genes Dev.18(21), 2614–2626 (2004).
  • Tsumura H , YoshidaT, SaitoH, Imanaka-YoshidaK, SuzukiN: Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice.Oncogene25(59), 7673–7679 (2006).
  • Kobbert C , MollmannC, SchafersMet al.: Transgenic model of cardiac rhabdomyosarcoma formation.J. Thorac Cardiovasc. Surg.136(5), 1178–1186 (2008).
  • Zibat A , UhmannA, NitzkiFet al.: Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts.Carcinogenesis30(6), 918–926 (2009).
  • Hahn H , NitzkiF, SchorbanT, HemmerleinB, ThreadgillD, RosemannM: Genetic mapping of a Ptch1-associated rhabdomyosarcoma susceptibility locus on mouse chromosome 2.Genomics84(5), 853–858 (2004).
  • Keller C , CapecchiMR: New genetic tactics to model alveolar rhabdomyosarcoma in the mouse.Cancer Res.65(17), 7530–7532 (2005).
  • Merlino G , KhannaC: Fishing for the origins of cancer.Genes Dev.21(11), 1275–1279 (2007).
  • Amstutz R , WachtelM, TroxlerHet al.: Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities.Cancer Res.68(10), 3767–3776 (2008).
  • Oesch S , WalterD, WachtelMet al.: Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma.Mol. Cancer Ther.8(7), 1838–1845 (2009).
  • De Giovanni C , MelaniC, NanniPet al.: Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin.Br. J. Cancer72(5), 1224–1229 (1995).
  • Scotlandi K , ManaraMC, NicolettiGet al.: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.Cancer Res.65(9), 3868–3876 (2005).
  • Kolb EA , GorlickR, HoughtonPJet al.: Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.Pediatr. Blood Cancer50(6), 1190–1197 (2008).
  • Huang F , GreerA, HurlburtWet al.: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.Cancer Res.69(1), 161–170 (2009).
  • Bjornsti MA , HoughtonPJ: The TOR pathway: a target for cancer therapy.Nat. Rev. Cancer4(5), 335–348 (2004).
  • Wan X , HelmanLJ: The biology behind mTOR inhibition in sarcoma.Oncologist12(8), 1007–1018 (2007).
  • Houghton PJ , MortonCL, KolbEAet al.: Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.Pediatr. Blood Cancer50(4), 799–805 (2008).
  • Wan X , HarkavyB, ShenN, GroharP, HelmanLJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.Oncogene26(13), 1932–1940 (2007).
  • Maris JM , CourtrightJ, HoughtonPJet al.: Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.Pediatr. Blood Cancer50(3), 581–587 (2008).
  • Maris JM , CourtrightJ, HoughtonPJet al.: Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.Pediatr. Blood Cancer51(1), 42–48 (2008).
  • Lollini PL , De GiovanniC, LanduzziL, NicolettiG, ScotlandiK, NanniP: Reduced metastatic ability of In vitro differentiated human rhabdomyosarcoma cells.Invasion Metastasis11(2), 116–124 (1991).
  • Sirri V , LeibovitchMP, LeibovitchSA: Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain.Oncogene22(36), 5658–5666 (2003).
  • Yang Z , ZhangJ, CongHet al.: A retrovirus-based system to stably silence GDF-8 expression and enhance myogenic differentiation in human rhabdomyosarcoma cells.J. Gene Med.10(8), 825–833 (2008).
  • Yang Z , MacQuarrieKL, AnalauEet al.: MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state.Genes Dev.23(6), 694–707 (2009).
  • Astolfi A , De GiovanniC, LanduzziLet al.: Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells.Gene274(1–2), 139–149 (2001).
  • Tanzarella S , LionelloI, ValentinisB, RussoV, LolliniPL, TraversariC: Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies.Cancer Immunol. Immunother.53(6), 519–524 (2004).
  • van den Broeke LT , PendletonCD, MackallC, HelmanLJ, BerzofskyJA: Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors.Cancer Res.66(3), 1818–1823 (2006).
  • Mackall CL , RheeEH, ReadEJet al.: A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.Clin. Cancer Res.14(15), 4850–4858 (2008).
  • Ecke I , PetryF, RosenbergerAet al.: Antitumor effects of a combined 5-aza-2´deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice.Cancer Res.69(3), 887–895 (2009).
  • Nanni P , SchiaffinoS, De GiovanniCet al.: RMZ: a new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin.Br. J. Cancer54(6), 1009–1014 (1986).
  • Neale G , SuX, MortonCLet al.: Molecular characterization of the pediatric preclinical testing panel.Clin. Cancer Res.14(14), 4572–4583 (2008).
  • Anderson J , RamsayA, GouldS, Pritchard-JonesK: PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma.Am. J. Pathol.159(3), 1089–1096 (2001).
  • Linardic CM , NainiS, HerndonJE, KesserwanC, QualmanSJ, CounterCM: The PAX3–FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.Cancer Res.67(14), 6691–6699 (2007).
  • Zhang Y , SchwartzJ, WangC: Comparative analysis of paired- and homeodomain-specific roles in PAX3–FKHR oncogenesis.Int. J. Clin. Exp. Pathol.2(4), 370–383 (2009).
  • Nishijo K , ChenQR, ZhangLet al.: Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.Cancer Res.69(7), 2902–2911 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.